Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders

Journal of the Formosan Medical Association

Volumn 109, Issue 12, 2010, Pages 862-878

  Liu, Hsin Tzu ^a   Chen, Chia Yen ^a   Kuo, Hann Chorng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Detrusor; Nerve growth factor; Overactive bladder; Urodynamics

Indexed keywords

BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR;

BLADDER NECK STENOSIS; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; HUMAN; LOWER URINARY TRACT SYMPTOM; OVERACTIVE BLADDER; REVIEW; SYMPTOM; URINE INCONTINENCE; URINE LEVEL;

EID: 79951893150     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60133-7     Document Type: Review

References (98)

1. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6(Suppl 11):S580-90.
2. DeWatcher S, Wyndale JJ. Frequency volume chart: a tool to evaluate bladder sensation. Neurourol Urodyn 2003; 22:638-43.
3. Nixon A, Colman S, Sabounjian L, et al. Validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604-7.
4. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175: 191-5.
5. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94.
6. Malone-Lee JG, Al-Buheissi A. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009;103:931-7.
7. Tanner R, Chambers P, Khadra MH, et al. The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 2000;85:1115-9.
8. Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 2000;161:273-84.
9. Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol 1999;57:583-606.
10. Clemow DB, Steers WD, Tuttle JB. Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol 2000;183:289-300.
11. Seki S, Sasaki K, Igawa Y, et al. Detrusor overactivity induced by increased levels of nerve growth factor in bladder afferent pathways in rats. Neurourol Urodyn 2003;22:375-7.
12. Lamb K, Gebhart GF, Bielefeldt K. Increased nerve growth factor expression triggers bladder overactivity. J Pain 2004; 5:150-6.
13. Yoshimura N, Bennett NE, Hayashi Y, et al. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 2006;26:10847-55.
14. Zvara P, Vizzard MA. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol 2007;7:1-11.
15. Guerios SD, Wang ZY, Bjorling DE. Nerve growth factor mediates peripheral mechanical hypersensitivity that accompanies experimental cystitis in mice. Neurosci Lett 2006;392:193-7.
16. Tong YC, Cheng JT. Changes in bladder nerve growth factor and p75 genetic expression in streptozotocin-induced diabetic rats. BJU Int 2005;96:1392-6.
17. Sasaki K, Chancellor MB, Phelan MW, et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J Urol 2002;168:1259-64.
18. Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997;79:572-7.
19. Birder LA, Wolf-Johnston A, Griffiths D, et al. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 2007;26:405-9.
20. Eryildirim B, Tarhan F, Gul AE, et al. Immunohistochemical analysis of low-affinity nerve growth factor receptor in the human urinary bladder. Urol Int 2006;77:76-80.
21. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006;175:2341-4.
22. Steers WD, Kolbeck S, Creedon D, et al. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991;88:1709-15.
23. Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 1999;161:438-41.
24. Dupont MC, Spitsberegen JM, Kim KB, et al. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 2000;166:1111-8.
25. Tuttle JB, Steers WD, Albo M, et al. Neural input regulates tissue NGF and growth of the adult rat urinary bladder. J Auton Nerv Syst 1994;49:147-58.
26. Steers WD, Tuttle JB. Mechanisms of diseases: the role of nerve growth factor in the pathophysiology of bladder disorders. Nature Clin Pract Urol 2006;3:101-10.
27. Lommatzsch M, Braun A, Mannsfeldt A, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic function. Am J Pathol 1999;155:1183-93.
28. Zvara P, Vizzard MA. Exogenous overexpression of NGF in the urinary bladder produces bladder overactivity and altered micturition circuity in the lumbosacral spinal cord. BMC Physiol 2007;7:9-19.
29. Kim JC, Park EY. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006;175:1773-6.
30. Yokoyama T, Kumon H, Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 2008;27:417-20.
31. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;74:977-82.
32. Chuang YC, Fraser MO, Yu U, et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 2001;65:975-9.
33. Hu VY, Zvara P, Dattilio A, et al. Decrease in bladder overactivity with REN1820 in rats with cyclophsphamide induced cystitis. J Urol 2005;173:1016-21.
34. Dmitrieva N, McMahon SB. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 1996;66: 87-97.
35. Bielefeldt K, Lamb K, Gebhart GF. Convergence of sensory pathways in the development of somatic and visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 2006; 291:G658-65.
36. Murray E, Malley SE, Qiao LY, et al. Cyclophosphamide induced cystitis alters neurotrophin and receptor tyrosine kinase expression in pelvic ganglia and bladder. J Urol 2004; 172:2434-9.
37. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007;70:463-8.
38. Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 2009;104:1476-81.
39. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008;179:2270-4.
40. Digesu GA, Khullar V, Cardozo L, et al. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003;22:105-8.
41. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001;166:550-3.
42. Blok B, Willemsen T, Holstege G. A PET study of brain control of micturition in humans. Brain 1997;120:111-21.
43. Fowler CJ. Neurological disorders of micturition and their treatment. Brain 1999;122:1213-31.
44. Liu HT, Liu AB, Chancellor MB, et al. Urinary nerve growth factor levels is correlated with severity of neurological impairment in patients with cerebrovascular accident. BJU Int 2009;104:1158-62.
45. Alleva E, Santucci D. Psychosocial vs. "physical" stress situations in rodents and humans: role of neurotrophins. Physiol Behav 2001;73:313-20.
46. Comelli MC, Guidolin D, Seren MS, et al. Time course, localization and pharmacological modulation of immediate early inducible genes, brain-derived neurotrophic factor and trkB messenger RNAs in the rat brain following photochemical stroke. Neuroscience 1993;55:473-90.
47. Stanzani L, Zoia C, Sala G, et al. Nerve growth factor and transforming growth factor-beta serum levels in acute stroke patients. Possible involvement of neurotrophins in cerebrovascular disease. Cerebrovasc Dis 2001;12: 240-4.
48. Bonini S, Lambiase A, Bonini S, et al. Nerve growth factor: an important molecule in allergic inflammation and tissue remodeling. Int Arch Allergy Immunol 1999;118:159-62.
49. Lindner MD, Gordon DD. Increased levels of truncated nerve growth factor receptor in urine of mildly demented patients with Alzheimer's disease. Arch Neurol 1993;50: 1054-60.
50. Aloe L, Bracci-Laudiero L, Bonini S, et al. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 1997;52:883-94.
51. Yamaguchi O. Response of bladder smooth muscle cells to obstruction: signal transduction and the role of mechanosensors. Urology 2004;63(Suppl 3A):11-6.
52. Steers WD, Kolbeck S, Creedon D, et al. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991;88:1709-15.
53. Nitti VW, Kim Y, Combs AJ. Voiding dysfunction following transurethral resection of the prostate: symptoms and urodynamic findings. J Urol 1997;157:600-3.
54. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008;72:104-8.
55. Steers WD, Creedon DJ, Tuttle JB. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 1996;155:379-85.
56. Yoshida M, Miyamae K, Iwashida H, et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004;63(3 Suppl 1):17-23.
57. Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical application. Naunyn Schmiedebergs Arch Pharmacol 2006;373:287-99.
58. Apostolidis A, Brady CM, Yiangou Y, et al. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and the effect of intravesical resiniferatoxin. Urology 2005;5:400-5.
59. Brady CM, Apostolidis AN, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004;93:770-6.
60. Brady C, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibers in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol 2004;46:247-53.
61. Smet PJ, Moore KH, Jonavicius J. Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 1997;77:37-49.
62. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-82.
63. Kim JC, Kim DB, Seo SI, et al. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int 2004;94:915-8.
64. Amaya F, Shimosato G, Nagano M, et al. NGF and GDNF differentially regulate TRPV1 expression that contribute to development of inflammatory thermal hyperalgesia. Eur J Neurosci 2004;20:2303-10.
65. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009;56:700-6.
66. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-5.
67. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66:94-8.
68. Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-9.
69. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005;192:1735-40.
70. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-a toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176: 177-85.
71. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 2006;50:684-709.
72. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868-72.
73. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002;4:S7-18.
74. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50.
75. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009;103:1668-72.
76. Kuo HC, Liu HT, Tyagi P, et al. Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency symptoms. LUTS 2010;2:88-94.
77. Smaldone MC, Vodovotz Y, Tyagi V, et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamideinduced cystitis. Urology 2009;73:421-6.
78. Tyagi P, Vodovotz Y, Kuo HC, et al. Urine cytokines exhibit the bladder inflammation in the overactive bladder; pilot study. Urology 2009;2:88-94.
79. Zvarova K, Murray E, Vizzard MA. Changes in galanin immunoreactivity in rat lumbosacral spinal cord and dorsal root ganglia after spinal cord injury. J Comp Neurol 2004; 475:590-603.
80. Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 2002;168:2269-74.
81. Cameron AA, Smith GM, Randall DC, et al. Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia. J Neurosci 2006;26: 2923-32.
82. Seki S, Sasaki K, Igawa Y, et al. Suppression of detrusorsphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol 2004;171:478-82.
83. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003;92:731-5.
84. Segal JL, Vassallo B, Kleeman S, et al. Prevalence of persistent and de novo overactive bladder symptoms after the tensionfree vaginal tape. Obstet Gynecol 2004;104:1263-9.
85. Doo CK, Hing B, Chung BJ, et al. Five-year outcomes of the tension-free vaginal tape procedure for treatment of female stress urinary incontinence. Eur Urol 2006;50: 333-8.
86. Duckett JR, Basu M. The predictive value of preoperative pressure-flow studies in the resolution of detrusor overactivity and overactive bladder after tension-free vaginal tape insertion. BJU Int 2007;99:1439-42.
87. Chuang FC, Kuo HC. Videourodynamic evaluation of urge syndrome following pubovaginal sling procedure for stress urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:1253-8.
88. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 2008;102:1440-4.
89. Yamaguchi O, Honda K, Nomiya M, et al. Defining overactive bladder as hypersensitivity. Neurourol Urodyn 2007; 26:904-7.
90. Kuo HC, Liu HT. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn 2009;28:78-81.
91. Cockayne DA, Hamilton SG, Zhu OM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000;407:1011-5.
92. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99.
93. nd edition. Plymouth, UK: Health Publication Ltd., 2002:85-161.
94. Kuo HC, Liu HT, Chancellor MB. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 2010;29:482-7.
95. Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/painful bladder syndrome and detrusor overactivity. BJU Int 2010;106:1681-5.
96. Erickson DR, Belchis DA, Dabbs DJ. Inflammatory cell types and clinical features of interstitial cystitis. J Urol 1997;158: 790-3.
97. Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008; 53:1245-53.
98. Smaldone MC, Vodovotz Y, Tyagi V, et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamideinduced cystitis. Urology 2009;73:421-6.